Getting a feeding tube before substantial weight loss may change the disease course and lengthen life with ALS, a study ...
As ALS progresses, annual healthcare costs for U.S. patients increase from an average of $31,000 to over $120,000, a Biogen ...
Neurosense is finalizing the protocol of a Phase 3 study of PrimeC for ALS, and plans to submit the protocol for FDA approval ...
HEALEY ALS, a platform trial testing multiple potential treatments for amyotrophic lateral sclerosis, is amending its master ...
Columnist Kristin Neva must take on more caregiver duties as her husband's ALS progresses, which means she must shift her ...
Dazucorilant, an oral cortisol modulator being developed by Corcept Therapeutics, didn’t significantly slow disease progression in people with amyotrophic lateral sclerosis (ALS) over a placebo, ...
The Centers for Medicare and Medicaid Services (CMS) has issued a directive requiring that Medicare Advantage plans cover Qalsody (tofersen) to treat people with amyotrophic lateral sclerosis (ALS) ...
The HEALEY ALS platform trial, which is simultaneously testing multiple potential treatments for amyotrophic lateral sclerosis (ALS), is amending its master protocol to allow a longer follow-up time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback